Pharmaceutical

Lupin and Takeda to commercialise Vonoprazan in India

Lupin has announced a non-exclusive patent licence agreement with Takeda for the commercialisation of Vonoprazan Tablets in India.

Sep 20, 2024 - 04:00
Lupin and Takeda to commercialise Vonoprazan in India
Lupin has announced a non-exclusive patent licence agreement with Takeda for the commercialisation of Vonoprazan Tablets in India.
Read the original article

Tags:

Previous Article

Organon makes $1.2bn play for Roivant’s immuno-dermatology subsidiary

Next Article

FDA approves Accord BioPharma’s HERCESSI for cancer treatment

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: FDA proposes changes to key approval pathway for medical devices, five years after promising

STAT+: FDA proposes changes to key approval pathway for...

Sep 12, 2023

STAT+: Wyden decries ‘astonishingly low’ tax rates for pharma companies as he probes business maneuvers

STAT+: Wyden decries ‘astonishingly low’ tax rates for ...

May 11, 2023

Resilience secures funds to enhance production of essential medicine components

Resilience secures funds to enhance production of essen...

Oct 6, 2024